Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
510actual
Sites
197
Countries
Argentina, Australia, Austria +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2013-09-25 | actual | When the study began enrolling |
| Primary completion | 2016-06-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2013-09-02 | estimated | When this record first appeared on the registry |
| Results posted | 2017-08-29 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions
- Drug: Selumetinib — also filed as AZD6244; ARRY-142886
- Drug: Docetaxel
- Drug: Placebo
- Drug: Pegylated G-CSF — also filed as Pegfilgrastim 6 mg
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS)
measured Measured at baseline until the date of first documented objective disease progression. Estimated final completion : approximately 3 years after first subject in (FSI)
Publications
- PMID 28492898 — linked by the registry
- PMID 26837474 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed